“This official CPSA ratification...means another milestone has been reached on our journey to bring the Syantra DX | Breast Cancer test to women around the world.”‍

CALGARY, Alberta., Nov 10, 2021 — Syantra Inc., a precision healthcare company that’s changing the way cancer is detected, starting with breast cancer, today announced the recent ratification of its College of Physicians and Surgeons of Alberta (CPSA) Lab Accreditation. Syantra received full approval of its CPSA Lab Accreditation status in July and has been awaiting official ratification in order to announce this significant achievement.

“We were thrilled to receive the provisional accreditation in July because it meant we could offer tests to patients from our new Calgary lab. It meant we could accelerate and begin to offer tests to the public,” said Bob Shepherd, President and Chief Executive Officer at Syantra. “This official CPSA ratification, which arrived late in October, means another milestone has been reached.

Any Alberta laboratory that performs and reports diagnostic tests to guide patient care needs to be CPSA accredited. It’s a rigorous assessment process based on Quality Management Systems (QMS), which are recognized by international health care external evaluation organizations.

“Syantra implemented a Quality Management System in 2017, when we registered and accredited our operations under the ISO 13485 standard for medical product manufacturing. Expanding this system to meet CPSA requirements was something we were readily able to do,” said Shepherd. “Quality systems form the backbone of what we do as a precision medicine company, so this is a critical focus for us.”‍